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Abstract
Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic
diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30% of the
population. Although applied for 100 years to cure allergy, SIT still faces several problems related to side effects and
limited efficacy. Currently, allergen-SIT is performed with vaccines based on allergen extracts that can cause severe,
often life threatening, anaphylactic reactions as well as new IgE sensitization to other allergens present in the extract.
Low patient adherence and high costs due to long duration (3 to 5 years) of treatment have been commonly reported.
Several strategies have been developed to tackle these issues and it became possible to produce recombinant
allergen-SIT vaccines with reduced allergenic activity.
Although performed for 102 years, allergen immunotherapy
(AIT) faces several problems related to its efficacy, side ef-
fects, low patient adherence and the high costs due to long
duration (3 to 5 years) of treatment [1,2]. The approaches
to improve the efficacy and safety of vaccine-based AIT
can be classified into different groups (Table 1).
Targeting T cells to induce T cell tolerance and bypass-
ing IgE binding to avoid IgE-mediated side effects is the
first approach [26]. T cell tolerance appears to be one of
the key mechanisms of action of AIT [27]. The conform-
ation dependence of B cell epitopes and linearity of the
amino acids sequence of T cell epitopes in the three
dimentional structure of an allergen has been targeted in
this group using allergen-fragments, fusions, hybrids and
chimeras [3,4,6,26]. The prototype of this approach is
peptide immunotherapy that utilizes linear T cell epitope
peptides [7,8,28]. A major advantage of these T cell tar-
geting approaches is that higher doses of allergens to be
sequentially administered, which is required to induce T
cell tolerance without the risk of anaphylaxis [12,26]. In
addition, recently allergen-specific B regulatory (reg) cells
have been demonstrated to be important. It appears that
these Breg cells increase within the first 3 months of AIT
and differentiate into IgG4-producing plasma cells. IL-10
coming from both B and T cells seem to be essential in
IgG4 production [29].
The second approach is the use of recombinant aller-
gens or their mixtures, with the aim of partially reconsti-
tuting an allergen extract. For example, a mixture of five
recombinant grass pollen allergens showed effectiveness
in reducing symptoms and the need for symptomatic
medication in people with allergies to grass pollen [13].
All treated subjects developed strong allergen-specific
IgG1 and IgG4 antibody responses. In another study of re-
combinant (r) Bet v 1 clinical improvement was observed
accompanied by marked increases in Bet v 1-specific IgG
levels, which were higher in the rBet v 1-treated group
than in the birch and nBet v 1-treated groups. The recom-
binant allergen also avoided new sensitizations. New IgE
specificities were induced in 3 of 29 patients treated with
birch pollen extract, but in none of the 32 rBet v 1-treated
or 29 nBet v 1-treated patients. No severe systemic adverse
events were observed in the rBet v 1-treated group [30].
There have been more than 10 clinical trials-all showing
increased clinical efficacy compared to placebo group-
completed by using recombinant allergens during the last
decade [31,32]. Recombinant allergens provide a significant
advantage in the problems of standardization of allergen
extracts.
Another important approach is to physically couple al-
lergens to stimulators of the innate immune response.
This area is very open to future developments, as there
are infinite possibilities for combinations owing to the ex-
istence of multiple immune stimulators and methods for
coupling [14-18]. Notably, the time, intensity and tissue
location of stimulation of the innate immune response by
the allergen is decisive in the induction of tolerance or
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immune activation. For example, house dust mites can use
Toll-like receptor 4 triggering in airway structural cells to
induce asthma/like inflammation in mice [33]. It is expected
that novel adjuvants may induce allergen-specific T cell tol-
erance with relatively less allergen doses and may direct the
unwanted Th2 response towards a Tregulatory response in
Table 1 Novel vaccine development for allergen-SIT
Type of the vaccine/approach Description and mechanism Current status
Bypassing IgE and targeting T cells
Fusion of major allergens [3] and
chimeric allergens [4]
Major allergens or their fragments are fused and expressed as a
single recombinant protein. IgE binding is attenuated, T cell
reactivity is preserved. Preventive effect on generation of IgE
is demonstrated in mice.
Effects in human cell cultures and mouse
models.
Hypoallergenic hybrid molecules [5] Derived from Der p 1 and Der p 2, reduced IgE reactivity of
hybrid proteins, induce higher T cell proliferation responses.
Effects in human cell cultures and mouse
models.
Fragments of major allergens [6] Major allergen (Bet v 1) is divided into nonIgE binding fragments.
IgE binding is attenuated and T cell reactivity is preserved.
A multi center clinical trial has been finalized.
Peptide immunotherapy [7-11] NonIgE binding T cell epitope peptides (Fel d 1, Api m 1) have
been used in cat and bee venom allergy.
Several promising clinical studies have been
performed. Safe and tolerable in cat allergics
Unrefolded native or
recombinant allergens [12]
Major recombinant allergens (Api m 1, Bet v 1) are not refolded
to the native conformation. This decreases or abolishes IgE
binding, but preserves T cell reactivity.
Several studies reported promising results.
Polymers of major allergens [6] Major allergen (Bet v 1) is trimerized. Mast cell, basophil degranulation
is attenuated, T cell reactivity is preserved in vitro.
A multi center clinical trial has been finalized.
Reconstitution of the natural extract with multiple recombinant allergens
Mixture of several major
recombinant allergens [13]
A mixture of five recombinant grass pollen allergens (Phl p 1,
Phl p 2, Phl p 5a, Phl p 5b, Phl p 6) reduced symptoms and need
for symptomatic medication in grass pollen allergic patients.
One clinical trial reported promising results.
Allergens coupled to adjuvants
GpG oligonucleotide-conjugated
allergens [14]
Major allergen (Amb a 1) is bound to a toll-like receptor
9-triggering CpG oligonucleotide.
A large multicenter clinical trial did not reach
endpoints, but the clinical efficacy was
robustly demonstrated.
Allergens coupled to virus-like
particles [15]
Der p 1 coupled to highly repetitive virus capside-like
recombinant particles
Rapid induction of high IgG antibody titers
was observed in healthy human volunteers.
Carbohydrate-based particles [16] Carbohydrate-based particles-bound rPhl p 5b induced a
stronger antibody and cytokine responses.
In murine models.
Hypoallergenic vaccine based on
allergen-derived peptides fused
to hepatitis B PreS [17]
Recombinant fusion proteins show reduced allergenic activity
in basophil activation and no IgE reactivity.
In murine models.
Monophosphoryl lipid A (MPL)
formulated with allergoid [18]
Pollen allergoid formulated with the Th1-inducing adjuvant
monophosphoryl lipid A (MPL) facilitates short-term SIT.
Results of clinical trials have been reported.
Novel routes of administration
Intralymphatic vaccination [19] Allergen-SIT vaccines administered directly into a lymph node.
The aim is to deliver high amounts of allergens into secondary
lymphatic organs.
Results of a clinical trial have been reported
to show safety and efficacy.
Epicutaneous vaccination [20] High numbers of antigen presenting cells (LCs), non-vascularized
area, safe, needle-free, and potentially self-administrable.
Clinical trial in grass pollen-induced
rhinoconjunctivitis demonstrated safety
and efficacy.
Fusion with immune response modifiers
Targeting FcγRII [21,22] Fusion of allergens with human Fcγ has been reported to inhibit
allergen-induced basophil and mast cell degranulation by
crosslinking Fcγ and FcεRI receptors.
Human cell cultures and mouse models.
Modular antigen translocation
(MAT) vaccines [23]
The fusion of transactivator of transcription (Tat) peptide to both
truncated invariant chain and allergens is able to target antigens
to the nascent MHC II molecules in the trans-golgi compartment.
Clinical trial is finalized and demonstrated
safety and efficacy with evidence of immune
regulation.
Combined treatment with immune response modifiers
Pre-treatment with anti-IgE mAb
before SIT [24,25]
To reduce SIT induced side effects. To enable relatively rapid dose
increase To use relatively high doses
Significantly fewer systemic allergic reactions,
more patients were able to reach the target
maintenance immunotherapy dose.
Akdis World Allergy Organization Journal 2014, 7:23 Page 2 of 5
http://www.waojournal.org/content/7/1/23
an earlier time frame. However, so far these approaches
did not end up with a fruitful outcome. The generation
and maintenance of allergen-specific T-cell tolerance is a
key step in healthy immune responses to allergens and
successful AIT. Breaking of peripheral T-cell tolerance to
allergens can lead to the development of allergies, but the
mechanisms are not completely understood. It was re-
cently demonstrated that certain innate immune response
signals and proinflammatory cytokines, such as IL-1β,
IL-6, TLR-4-ligands and TLR8-ligands break allergen-
specific CD4 T-cell tolerance in normally unresponsive
subjects, which might lead to the development or exacer-
bation of allergic diseases after encountering microbes or
inflammatory conditions. The usage of novel adjuvants
should be considered also in this perspective [34].
The fourth approach is varying routes of vaccine admin-
istration. A meta-analysis of the double-blind, placebo-
controlled trials has shown that sublingual immunotherapy
(SLIT) is clinically efficacious with a treatment benefit
approximately half of that achieved with subcutaneous
AIT [35]. Sustained disease-modifying effects of this
type of therapy have been confirmed in large-scale ran-
domized, double-blind, placebo-controlled trials as well as
in children [36,37]. The immunological mechanisms of
SLIT seem to be similar to subcutaneous AIT, although
the magnitude of the change in most parameters is mod-
est or no changes have been observed. Immune tolerance
induced by SLIT is associated with Treg cells, IL-10 pro-
duction, increases in sublingual Foxp3-expressing cells
and elevated allergen-specific IgG4, IgA and serum in-
hibitory activity for IgE-facilitated allergen binding to B
cells [38,39]. Recently, allergen-specific FOXP3+ Treg
cells have been found in human lingual and palatine ton-
sils in humans, and these cells may participate in oral tol-
erance and SLIT [40]. Oral mucosal tissue is naturally
tolerogenic, and does not show acute inflammation des-
pite high levels of bacterial colonization, and shows rapid
wound healing in the absence of scarring. A C-type lectin
receptor, SIGNR-1 (also called Cd209b), helps to condition
dendritic cells in the gastrointestinal lamina propria for
the induction of oral tolerance in a model of food-induced
anaphylaxis. These results suggest that sugar-modified an-
tigens might be used to induce oral tolerance by targeting
SIGNR1 and lamina propria DCs [41]. Recently the intra-
lymphnode and epicutaneous routes have been tested.
Both routes showed similar efficacy to subcutaneous injec-
tion immunotherapy in grass pollen allergy, but less appli-
cations and lower total doses of allergen were required
using these routes [19,20]. Intralymphatic administration
induced T cell responses with strong cytotoxic activity and
IFN-γ production that conferred long-term protection
against viral infections and tumors.
In another approach, the coaggregation of FcεRI and
FcγRII receptors that inhibit FcεRI signaling and the fusion
of allergens to human Fcγ have been reported to inhibit
allergen-induced basophil and mast cell degranulation by
crosslinking Fcγ and FcεRI receptors [21,22]. In a dif-
ferent approach, the major cat allergen Fel d 1 was
cloned and expressed together with a human immune de-
ficiency virus protein, TAT-derived membrane transloca-
tion domain, and a truncated peptide of the invariant
chain (modular antigen translocation (MAT)-Fel d 1) [42].
This MAT-Fel d 1 vaccine is efficiently internalized and
potently presented to T cells by antigen-presenting cells,
and induced T cell responses at doses which were ap-
proximately 100x lower than those of the native aller-
gens. In a double-blind, placebo-controlled clinical trial,
the MAT-Fel d 1 vaccine with alum adjuvant was adminis-
tered in three increasing doses (1 μg, 3 μg, 10 μg) into in-
guinal, lymph nodes at 4 week intervals. In addition to a
good safety profile, individuals who were allergic to cats
and treated with the MAT-Fel d 1 vaccines became clinic-
ally tolerant to nasal challenge of cat dander extract in
parallel with increased serum IgG4 [23]. The findings were
not reproduced in another study of intralymphatic im-
munotherapy [43].
In addition to physical fusion, there is also a huge po-
tential for combining o conventional and novel methods
of AIT with immune response modifiers. For example,
anti-IgE combined with AIT has been evaluated in sev-
eral studies [24], and resulted in a significant decrease
in the risk of anaphylaxis caused by rush immunotherapy
(a rapid dose increment approach to reach the mainten-
ance dose as quick as possible) and improved rescue
medication scores (the need for a rescue medication to
suppress the symptoms: for example anti-histamines for
allergic rhinitis) of AIT with a good safety profile [24,44].
In a recent study, eighteen weeks' treatment of omalizu-
mab in combination with AIT in patients with sea-
sonal allergic rhinitis and comorbid seasonal allergic
asthma reduced the symptom load during the treat-
ment period but showed no prolonged effect during
treatment with AIT only [25]. Combination strategies
with biological immune response modifiers are ex-
pected to substantially expand the treatment scope of
AIT. Overall, there has been tremendous progress in ad-
dressing the challenge of improving efficacy and safety
of AIT, which is still the only approach for curing al-
lergic diseases. In addition, this strategy is still open to
further developments, which are expected to improve its
application to other diseases related to dysregulation of
the immune system.
Conclusion
Currently, allergen-specific immunotherapy is the only
available curative treatment of allergic diseases as it can in-
duce long-term allergen-specific immune tolerance using
multiple mechanisms. AIT is beneficial for a significant
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fraction of the treated individuals, however life-threatening
side effects can occur. Due to the long duration of the
treatment there is a problem with full adherence to the
therapy. Whereas it can be curative in some individuals,
there are non responders to treatment. To overcome these
problems, it is crucial to develop advanced vaccines. In
addition, the discovery of reliable biomarkers to select pa-
tients with a good clinical response is important. Notably,
the AIT-based curative approaches may also be promising
for the prevention of allergic disease. A greater under-
standing of the underlying disease mechanisms in allergic
diseases could bring the possibility of cure in a larger pa-
tient population nearer to reality.
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